Nothing Special   »   [go: up one dir, main page]

Moreno et al., 2014 - Google Patents

Striatal volume deficits in children with ADHD who present a poor response to methylphenidate

Moreno et al., 2014

View PDF
Document ID
863933180414038438
Author
Moreno A
Duno L
Hoekzema E
Picado M
Martin L
Fauquet J
Vives-Gilabert Y
Bulbena A
Vilarroya O
Publication year
Publication venue
European child & adolescent psychiatry

External Links

Snippet

Methylphenidate (MPH) is the first choice of medical treatment for attention- deficit/hyperactivity disorder (ADHD). Its mechanism of action is to inhibit the reuptake of dopamine and noradrenaline mainly in the region of the striatum. It has been estimated that …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • G06F19/345—Medical expert systems, neural networks or other automated diagnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Similar Documents

Publication Publication Date Title
Jauhar et al. The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study
Murrough et al. The effect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding
Hirvonen et al. Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C] WAY-100635
Brown et al. Increased glutamate concentration in the auditory cortex of persons with autism and first‐degree relatives: a 1H‐MRS study
Moreno et al. Striatal volume deficits in children with ADHD who present a poor response to methylphenidate
DuBois et al. Characterization of age/sex and the regional distribution of mglur5 availability in the healthy human brain measured by high-resolution [11 c] abp688 pet
Ceccarini et al. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia
Bessette et al. White matter abnormalities in adolescents with major depressive disorder
Harrison et al. Altered corticostriatal functional connectivity in obsessive-compulsive disorder
Bracht et al. Cortico-cortical white matter motor pathway microstructure is related to psychomotor retardation in major depressive disorder
MacMaster et al. Disorder-specific volumetric brain difference in adolescent major depressive disorder and bipolar depression
Vanicek et al. The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography
Claassen et al. Mesocorticolimbic hemodynamic response in Parkinson's disease patients with compulsive behaviors
Cervenka et al. Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum
O’Daly et al. Amphetamine sensitization alters reward processing in the human striatum and amygdala
Moresco et al. Fluvoxamine treatment and D2 receptors: a pet study on OCD drug-naive patients
KR20220100851A (en) Neuromelanin-sensitive MRI to evaluate Parkinson's disease
US20230389854A1 (en) Neuromelanin-sensitive mri and methods of use thereof
Schafer et al. Imaging habenula volume in schizophrenia and bipolar disorder
Hesse et al. Central serotonin transporter availability in highly obese individuals compared with non-obese controls: A [11 C] DASB positron emission tomography study
Whiteside et al. Decreased caudate N-acetyl-l-aspartic acid in pediatric obsessive-compulsive disorder and the effects of behavior therapy
Gustin et al. Subtle alterations in brain anatomy may change an individual’s personality in chronic pain
Dalrymple et al. Cholinergic nucleus 4 atrophy and gait impairment in Parkinson’s disease
Madsen et al. Cognitive function is related to fronto-striatal serotonin transporter levels–a brain PET study in young healthy subjects
Treyer et al. Reduced uptake of [11C]‐ABP688, a PET tracer for metabolic glutamate receptor 5 in hippocampus and amygdala in Alzheimer’s dementia